JL19001
/ Jecho Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 11, 2026
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
(clinicaltrials.gov)
- P1 | N=14 | Recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF • CXCL8 • IL4 • KRAS • MET • NRAS
August 07, 2026
JL19001-NMIBC: A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
May 23, 2026
A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
(clinicaltrials.gov)
- P1 | N=14 | Not yet recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1 trial • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Lung Cancer • Lymphoma • Melanoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF • CXCL8 • IL4 • KRAS • MET • NRAS
April 23, 2026
A Phase I/II Study of JL19001 Injection Alone or in Combination with BCG in Subjects with High Risk Non-Muscle Invasive Bladder Cancer.
(ChiCTR)
- P1/2 | N=111 | Sponsor: West China Hospital of Sichuan University; Jecho Biopharmaceuticals Co., Ltd.
New P1/2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CXCL8 • IL4
March 20, 2026
JL19001-NMIBC: A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1